6[3]Fox RI. Mechanism of action of leflunomide in RA[J].J Rheum .1998,25(Suppl 53)∶S27-S32．
7[4]Smolen JS,Kalden JR,Scott DL，et al.Efficacy and safety of le flunomid e compared with placebo and sulphasalazine in active RA:a double-blind, randomi zed,multicenter trial[J].Lancet,1999,353,9149∶259-266．
8[5]Rozman B.Clinical experience with leflunomide in RA[J].J Rheu m，1998,25 (Suppl 53)∶S20-S26．
9[6]Weaver A,Caldwell J,Olsen N,et al.Treatment of active RA with lefluno mide compared to placebo or MTX[C].Poster at 62nd ACR in San Diego, 1998.
10[7]Moldovan F,Pelletier JP,Jolicoeur FC,et al.Diacerhein and rhe in redu ce the ICE induced IL-1β and IL-18 activation in human osteoarthritic cartila ge[J].Osteoarthritis and Cartilage，2000,8(3)∶186-196.
1Zimmermann KC, Sarbia M, Weber AA, et al. Cycloxygenase-2 expression in human esophageal carcinoma[J]. Cancer Res, 1999,59:198-204
2Sheng H,Shao J,Kirdland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2[J]. J Clin Invest, 1997,51:1124
3Graham D Y. Prevenyion of gastroduodenal injury induced by nonsteroidal antiinflanatory drug therapy[J]. Gastroenterology, 1999,96:675
4韩国柱.抗血栓药物的研究进展[J].医药导报,2000,6(10):1-2.
5Steward WF,Kawas C, Corrada M, et al. Risk lf Alzheimer's disease and duration of NSAID use[J]. Neurol, 1997,47:626
6Cryer B, Feldman M. Cyclooxygenase-l and cyclooxygenase2selectivity lf pidely used steroidal antiinflammtory drugs[J]. Am J Med, 1998,66:104
